$Edgewise Therapeutics (EWTX.US)$ NEWS Edgewise Therapeutics...
NEWS
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Positive two-year topline results from the ARCH trial show stabilization of NSAA scores with sevasemten treatment in adults with Becker Muscular Dystrophy.
Significant decreases in muscle damage biomarkers CK and TNNI2 were observed in participants treated with sevasemten.
Sevasemten was well-tolerated with no discontinuations or dose reductions due to adverse events.
The results support the potential of sevasemten to preserve function and halt disease progression in Becker Muscular Dystrophy.
Positive two-year topline results from the ARCH trial show stabilization of NSAA scores with sevasemten treatment in adults with Becker Muscular Dystrophy.
Significant decreases in muscle damage biomarkers CK and TNNI2 were observed in participants treated with sevasemten.
Sevasemten was well-tolerated with no discontinuations or dose reductions due to adverse events.
The results support the potential of sevasemten to preserve function and halt disease progression in Becker Muscular Dystrophy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
510Followers
65Following
3198Visitors
Follow